[1]
|
Stray-Pedersen, A., Abrahamsen, T.G. and Frøland, S.S. (2000) Primary Immunodeficiency Diseases in Norway. Jour-nal of Clinical Immunology, 20, 477-485. https://doi.org/10.1023/A:1026416017763
|
[2]
|
Devriendt, K., Kim, A., Mathijs, G., et al. (2001) Constitutively Activating Mutation in WASP Causes X-Linked Severe Congenital Neutropenia. Nature Genetics, 27, 313-317. https://doi.org/10.1038/85886
|
[3]
|
Ancliff, P.J., Blundell, M.P., Cory, G.O., et al. (2006) Two Novel Activating Mutations in the Wiskott-Aldrich Syndrome Protein Result in Congenital Neutropenia. Blood, 108, 2182-2189. https://doi.org/10.1182/blood-2006-01-010249
|
[4]
|
Beel, K., Cotter, M.M., Blatny, J., et al. (2009) A Large Kindred with X-Linked Neutropenia with an I294T Mutation of the Wiskott-Aldrich Syndrome Gene. British Journal of Haematology, 144, 120-126.
https://doi.org/10.1111/j.1365-2141.2008.07416.x
|
[5]
|
Kobayashi, M., Yokoyama, K., Shimizu, E., et al. (2018) Phenotype-Based Gene Analysis Allowed Successful Diagnosis of X-Linked Neutropenia Associated with a Novel WASp Mutation. Annals of Hematology, 97, 367-369.
https://doi.org/10.1007/s00277-017-3134-3
|
[6]
|
Blundell, M.P., Worth, A., Bouma, G. and Thrasher, A.J. (2010) The Wiskott-Aldrich Syndrome: The Actin Cytoskeleton and Immune Cell Function. Disease Markers, 29, 157-175. https://doi.org/10.1155/2010/781523
|
[7]
|
Malinova, D., Fritzsch, M., Nowosad, C.R., et al. (2016) WASp-Dependent Actin Cytoskeleton Stability at the Dendritic Cell Immunological Synapse is Required for Extensive, Functional T Cell Contacts. Journal of Leukocyte Biology, 99, 699-710. https://doi.org/10.1189/jlb.2A0215-050RR
|
[8]
|
Westerberg, L.S., de la Fuente, M.A., Wermeling, F., et al. (2008) WASP Confers Selective Advantage for Specific Hematopoietic Cell Populations and Serves a Unique Role in Marginal Zone B-Cell Homeostasis and Function. Blood, 112, 4139-4147. https://doi.org/10.1182/blood-2008-02-140715
|
[9]
|
Gismondi, A., Cifaldi, L., Mazza, C., et al. (2004) Impaired Natural and CD16-Mediated NK Cell Cytotoxicity in Patients with WAS and XLT: Ability of IL-2 to Correct NK Cell Functional Defect. Blood, 104, 436-443.
https://doi.org/10.1182/blood-2003-07-2621
|
[10]
|
Locci, M., Draghici, E., Marangoni, F., et al. (2009) The Wis-kott-Aldrich Syndrome Protein is Required for iNKT Cell Maturation and Function. Journal of Experimental Medicine, 206, 735-742. https://doi.org/10.1084/jem.20081773
|
[11]
|
Lorenzi, R., Brickell, P.M., Katz, D.R., Kinnon, C. and Thrasher, A.J. (2000) Wiskott-Aldrich Syndrome Protein Is Necessary for Efficient IgG-Mediated Phagocytosis. Blood, 95, 2943-2946.
https://doi.org/10.1182/blood.V95.9.2943.009k17_2943_2946
|
[12]
|
Ochs, H.D., Slichter, S.J., Harker, L.A., et al. (1980) The Wiskott-Aldrich Syndrome: Studies of Lymphocytes, Granulocytes, and Platelets. Blood, 55, 243-252. https://doi.org/10.1182/blood.V55.2.243.243
|
[13]
|
Prislovsky, A., Zeng, X., Sokolic, R.A., et al. (2013) Platelets from WAS Patients Show an Increased Susceptibility to ex Vivo Phagocytosis. Platelets, 24, 288-296. https://doi.org/10.3109/09537104.2012.693991
|
[14]
|
Marathe, B.M., Prislovsky, A., Astrakhan, A., et al. (2009) Antiplatelet Antibodies in WASP(−) Mice Correlate with Evidence of Increased in Vivo Platelet Consumption. Experi-mental Hematology, 37, 1353-1363.
https://doi.org/10.1016/j.exphem.2009.08.007
|
[15]
|
Gröttum, K.A., Hovig, T., Holmsen, H., et al. (1969) Wis-kott-Aldrich Syndrome: Qualitative Platelet Defects and Short Platelet Survival. British Journal of Haematology, 17, 373-388. https://doi.org/10.1111/j.1365-2141.1969.tb01383.x
|
[16]
|
Baldini, M.G. (1972) Nature of the Platelet De-fect in the Wiskott-Aldrich Syndromee. Annals of the New York Academy of Sciences, 201, 437-444. https://doi.org/10.1111/j.1749-6632.1972.tb16316.x
|
[17]
|
Mahlaoui, N., Pellier, I., Mignot, C., et al. (2013) Char-acteristics and Outcome of Early-Onset, Severe Forms of Wiskott- Aldrich Syndrome. Blood, 121, 1510-1516. https://doi.org/10.1182/blood-2012-08-448118
|
[18]
|
Jin, Y., Mazza, C., Christie, J.R., et al. (2004) Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): Hotspots, Effect on Transcription, and Translation and Pheno-type/Genotype Correlation. Blood, 104, 4010-4019.
https://doi.org/10.1182/blood-2003-05-1592
|
[19]
|
Imai, K., Morio, T., Zhu, Y., et al. (2004) Clinical Course of Pa-tients with WASP Gene Mutations. Blood, 103, 456-464.
https://doi.org/10.1182/blood-2003-05-1480
|
[20]
|
Ochs, H.D. and Thrasher, A.J. (2006) The Wiskott-Aldrich Syn-drome. Journal of Allergy and Clinical Immunology, 117, 725-738. https://doi.org/10.1016/j.jaci.2006.02.005
|
[21]
|
Chen, N., Zhang, Z.-Y., Liu, D.-W., et al. (2015) The Clinical Fea-tures of Autoimmunity in 53 Patients with Wiskott- Aldrich Syndrome in China: A Single-Center Study. European Journal of Pediatrics, 174, 1311-1318.
https://doi.org/10.1007/s00431-015-2527-3
|
[22]
|
Moratto, D., Giliani, S., Bonfim, C., et al. (2011) Long-Term Outcome and Lineage-Specific Chimerism in 194 Patients with Wiskott-Aldrich Syndrome Treated by Hematopoietic Cell Transplantation in the Period 1980-2009: An International Collaborative Study. Blood, 118, 1675-1684. https://doi.org/10.1182/blood-2010-11-319376
|
[23]
|
Davis, B.R. and Candotti, F. (2009) Revertant Somatic Mosai-cism in the Wiskott-Aldrich Syndrome. Immunologic Research, 44, 127-131. https://doi.org/10.1007/s12026-008-8091-4
|
[24]
|
Albert, M.H., Notarangelo, L.D. and Ochs, H.D. (2011) Clinical Spectrum, Pathophysiology and Treatment of the Wiskott-Aldrich Syndrome. Current Opinion in Hematology, 18, 42-48.
https://doi.org/10.1097/MOH.0b013e32834114bc
|
[25]
|
Medina, S.S., Siqueira, L.H., Colella, M.P., et al. (2017) Intermittent Low Platelet Counts Hampering Diagnosis of X-Linked Thrombocytopenia in Children: Report of Two Un-related Cases and a Novel Mutation in the Gene Coding for the Wiskott-Aldrich Syndrome Protein. BMC Pediatrics, 17, Article No. 151.
https://doi.org/10.1186/s12887-017-0897-6
|
[26]
|
Albert, M.H., Bittner, T.C., Nonoyama, S., et al. (2010) X-Linked Thrombocytopenia (XLT) due to WAS Mutations: Clinical Characteristics, Long-Term Outcome, and Treatment Options. Blood, 115, 3231-3238.
https://doi.org/10.1182/blood-2009-09-239087
|
[27]
|
Chiang, S.C.C., Vergamini, S.M., Husami, A., et al. (2018) Screening for Wiskott-Aldrich Syndrome by Flow Cytometry. Journal of Allergy and Clinical Immunology, 142, 333-335. https://doi.org/10.1016/j.jaci.2018.04.017
|
[28]
|
Giliani, S., Fiorini, M., Mella, P., et al. (1999) Prenatal Molecular Diagnosis of Wiskott-Aldrich Syndrome by Direct Mutation Analysis. Prenatal Diagnosis, 19, 36-40.
https://doi.org/10.1002/(SICI)1097-0223(199901)19:1<36::AID-PD458>3.0.CO;2-V
|
[29]
|
Bryant, N. and Watts, R. (2011) Thrombocytopenic Syndromes Masquerading as Childhood Immune Thrombocytopenic Purpura. Clinical Pe-diatrics, 50, 225-230. https://doi.org/10.1177/0009922810385676
|
[30]
|
Fathi, M., Shahraki, H., Rahmani, E.S., et al. (2019) Whole Exome Sequencing of an X-Linked Thrombocytopenia Patient with Normal Sized Platelets. Avicenna Journal of Medical Biotechnology, 11, 253-258.
|
[31]
|
Ochs, H.D. (2002) The Wiskott-Aldrich Syndrome. The Israel Medical Association Journal: IMAJ, 4, 379-384.
|
[32]
|
Gabelli, M., Marzollo, A., Notarangelo, L.D., Basso, G. and Putti, M.C. (2017) Eltrombopag Use in a Patient with Wiskott-Aldrich Syndrome. Pediatric Blood & Cancer, 64, e26692. https://doi.org/10.1002/pbc.26692
|
[33]
|
Mullen, C.A., Anderson, K.D. and Blaese, R.M. (1993) Splenectomy and/or Bone Marrow Transplantation in the Management of the Wiskott-Aldrich Syndrome: Long-Term Follow-up of 62 Cases. Blood, 82, 2961-2966.
https://doi.org/10.1182/blood.V82.10.2961.2961
|
[34]
|
Orange, J.S., Roy-Ghanta, S., Mace, E.M., et al. (2011) IL-2 Induces a WAVE2-Dependent Pathway for Actin Reorganization That Enables WASp-Independent Human NK Cell Function. The Journal of Clinical Investigation, 121, 1535-1548. https://doi.org/10.1172/JCI44862
|
[35]
|
Jyonouchi, S., Gwafila, B., Gwalani, L.A., et al. (2017) Phase I Trial of Low-Dose Interleukin 2 Therapy in Patients with Wis-kott-Aldrich Syndrome. Clinical Immunology, 179, 47-53. https://doi.org/10.1016/j.clim.2017.02.001
|
[36]
|
Shekhovtsova, Z., Bonfim, C., Ruggeri, A., et al. (2017) A Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation for Children with Wiskott-Aldrich Syndrome. Haematologica, 102, 1112-1119.
https://doi.org/10.3324/haematol.2016.158808
|
[37]
|
Burroughs, L.M., Petrovic, A., Brazauskas, R., et al. (202) Excellent Outcomes Following Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: A PIDTC Report. Blood, 135, 2094-2105.
https://doi.org/10.1182/blood.2019002939
|
[38]
|
Mallhi, K.K., Petrovic, A. and Ochs, H.D. (2021) Hematopoietic Stem Cell Therapy for Wiskott-Aldrich Syndrome: Improved Outcome and Quality of Life. Journal of Blood Medicine, 12, 435-447.
https://doi.org/10.2147/JBM.S232650
|
[39]
|
Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010) Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome. New England Journal of Medicine, 363, 1918-1927. https://doi.org/10.1056/NEJMoa1003548
|
[40]
|
Braun, C.J., Boztug, K., Paruzynski, A., et al. (2014) Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity. Science Translational Medicine, 6, Article No. 227ra33.
|
[41]
|
Abina, S.H.-B., Gaspar, H.B., Blondeau, J., et al. (2015) Outcomes Following Gene Therapy in Pa-tients with Severe Wiskott-Aldrich Syndrome. JAMA, 313, 1550-1563. https://doi.org/10.1001/jama.2015.3253
|
[42]
|
Castiello, M.C., Scaramuzza, S., Pala, F., et al. (2015) B-Cell Recon-stitution after Lentiviral Vector-Mediated Gene Therapy in Patients with Wiskott-Aldrich Syndrome. Journal of Allergy and Clinical Immunology, 136, 692-702.
https://doi.org/10.1016/j.jaci.2015.01.035
|
[43]
|
Morris, E.C., Fox, T., Chakraverty, R., et al. (2017) Gene Therapy for Wiskott-Aldrich Syndrome in a Severely Affected Adult. Blood, 130, 1327-1335. https://doi.org/10.1182/blood-2017-04-777136
|
[44]
|
Magnani, A., Semeraro, M., Adam, F., et al. (2022) Long-Term Safety and Efficacy of Lentiviral Hematopoietic Stem/ Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome. Nature Medicine, 28, 71-80.
https://doi.org/10.1038/s41591-021-01641-x
|